Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
Fulgent Genetics, Inc. (FLGT)
Last fulgent genetics, inc. earnings: 3/10 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fulgentgenetics.com
Company Research
Source: Business Wire
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, was presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on June 2, 2024 in Chicago, Illinois.Of eleven head and neck squamous cell carcinoma (HNSCC) evaluable patients with weekly dose levels from 15 mg/m2 to 160 mg/m2, five (45%) had a partial response and three (27%) had stable disease by RECIST. Three out of five HNSCC patients with PR had previously been treated with taxane. The duration of follow-up (months), median (range) is 4.0 (1.0 – 15.0). No high-grade neuropathy has been noted to date. FID-007 demonstrates preliminary evidence of anti-tumor activity in heavily pre-treated HNSCC patients across different primary tumor sites, wi
Show less
Read more
Impact Snapshot
Event Time:
FLGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FLGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FLGT alerts
High impacting Fulgent Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
FLGT
News
- What Is Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Share Price Doing? [Yahoo! Finance]Yahoo! Finance
- Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual MeetingBusiness Wire
- Moffitt and Fulgent Pharma partner on personalised cancer therapies [Yahoo! Finance]Yahoo! Finance
- Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics [Yahoo! Finance]Yahoo! Finance
FLGT
Earnings
- 5/3/24 - Beat
FLGT
Sec Filings
- 6/4/24 - Form 4
- 6/4/24 - Form 4
- 6/4/24 - Form 4
- FLGT's page on the SEC website